Endovia Health Sciences, Inc.
No enriched coverage for $EDVA in the last 7 days.
No SEC Form 4 filings for $EDVA in the last 30 days.
See all $EDVA insider activity →Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On September 30, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Maste
Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway Companies to Meet Formally with FDA’s Center for Veterinary Medicine on Novembe
Endovia Health Sciences (EDVA) received FDA minor-use status for CannEpil, a treatment for canine bone cancer pain, enabling a conditional approval pathway. The company will meet with the FDA on Nov. 19 and plans U.S. manufacturing for a potential 2027 launch, pending approvals.
Recent EDVA coverage spans corporate actions, regulation and earnings.
Small private placement likely causes negligible price movement.
Regulatory milestone could lift the stock as investors price in a path to approval and future revenue.
The regulatory milestone reduces time to market and may boost investor sentiment.
Potential upside if conditional approval is granted; downside risk if FDA delays or rejects.
The capital infusion provides runway for regulatory and clinical milestones, likely supporting short‑term price stability.
AlphAI scores every news story that mentions EDVA with an AI model for sentiment and relevance, and aggregates insider trades from Endovia Health Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On September 30, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 526,582 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Maste
1 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway Companies to Meet Formally with FDA’s Center for Veterinary Medicine on Novembe
2 min readEndovia Health Sciences (EDVA) received FDA minor-use status for CannEpil, a treatment for canine bone cancer pain, enabling a conditional approval pathway. The company will meet with the FDA on Nov. 19 and plans U.S. manufacturing for a potential 2027 launch, pending approvals.
1 min readEndovia Health Sciences (EDVA) and Lupvindol BioSciences announced that the FDA determined CannEpil, a CBD/THC oral solution for canine bone cancer pain, qualifies for the MUMS program, enabling a conditional approval pathway. The companies plan to meet with the FDA in November and aim for a potential 2027 commercial launch, pending regulatory approval and manufacturing readiness.
2 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 18, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an agreement (the “Letter Agreement”) with C/M Capital Master Fund, LP (the “Investor”) pursuant to which the Investor as a coun
1 min readWorthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.
2 min readEndovia Health Sciences (AMEX:EDVA) stock rose 47.83% in after-hours trading to $0.34 after securing initial funding from C/M Capital Master Fund. The funds support CannEpil's development, including FDA-regulated veterinary programs. The company has a market cap of $1.61M and a 52-week range of $0.23-$0.46.
1 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Endovia Health Sciences Closes Initial $500,000 Financing to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways Initial funding represents first tranche of previously announced $1 million C/M Capital commitment supporting CannEp
2 min readEndovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F
1 min readEndovia Health Sciences, Inc. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Endovia Health Sciences, Inc. (the “Company”) entered into an Employment Agreement (each, an “Agreement”) with each of Brady Cobb for his employment as Interim Chief Executive Officer of the Company and Mich
1 min read
